fujirebio - MRCHF

MRCHF

Close Chg Chg %
14.45 1.52 10.52%

Closed Market

15.97

+1.52 (10.52%)

Volume: 1.65K

Last Updated:

Jun 7, 2024, 2:58 PM EDT

Company Overview: fujirebio - MRCHF

MRCHF Key Data

Open

$15.97

Day Range

15.97 - 15.97

52 Week Range

14.45 - 19.07

Market Cap

$908.53M

Shares Outstanding

56.82M

Public Float

52.03M

Beta

0.20

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$0.78

Yield

525.34%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

84.05

 

MRCHF Performance

No Data Available

MRCHF Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings
Full Ratings ➔

About fujirebio - MRCHF

H.U. Group Holdings, Inc. provides the strategic planning, investor relations, public relations, and supervisory management of the entire group. It operates through the following segments: Contracted Clinical Testing, Clinical Laboratory Testing, Sterilization related, New Development Business and Others. The Contracted Clinical Testing segment offers clinical laboratory testing services; collecting consigned specimens of patients from medical institutions, conducting analyses and reporting the test results back. The Clinical Laboratory Testing segment develops, manufactures and sales diagnostic products globally that are used at medical field for early detection and diagnosis. The Sterilization related segment provides general solutions to the issues facing operating rooms and central materials rooms. It establishes new out-of-hospital centers and promoting automation of operations. The New Development Business and Others segment pertains to newly established food, environment and cosmetic inspection businesses. The company was founded on December 18, 1950 and is headquartered in Tokyo, Japan.

MRCHF At a Glance

H.U. Group Holdings, Inc.
Shinjuku Mitsui Building, 8/F
Tokyo, Tokyo 163-0408
Phone 81-3-5909-3335 Revenue 1.64B
Industry Medical/Nursing Services Net Income -52,232,915.76
Sector Health Services Employees 5,295
Fiscal Year-end 03 / 2025
View SEC Filings

MRCHF Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 0.56
Price to Book Ratio 0.974
Price to Cash Flow Ratio 8.023
Enterprise Value to EBITDA 10.276
Enterprise Value to Sales 0.73
Total Debt to Enterprise Value 0.453

MRCHF Efficiency

Revenue/Employee 309,467.847
Income Per Employee -9,864.573
Receivables Turnover 5.284
Total Asset Turnover 0.777

MRCHF Liquidity

Current Ratio 1.923
Quick Ratio 1.573
Cash Ratio 0.623

MRCHF Profitability

Gross Margin 24.167
Operating Margin -1.707
Pretax Margin -3.215
Net Margin -3.188
Return on Assets -2.476
Return on Equity -5.049
Return on Total Capital -3.522
Return on Invested Capital -3.436

MRCHF Capital Structure

Total Debt to Total Equity 57.503
Total Debt to Total Capital 36.509
Total Debt to Total Assets 27.744
Long-Term Debt to Equity 47.785
Long-Term Debt to Total Capital 30.339
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Fujirebio - MRCHF

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
2.10B 2.43B 1.93B 1.64B
Sales Growth
+21.15% +15.51% -20.74% -14.89%
Cost of Goods Sold (COGS) incl D&A
1.41B 1.46B 1.30B 1.24B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
117.80M 130.16M 145.32M 144.33M
Depreciation
- - - -
-
Amortization of Intangibles
- - - -
-
COGS Growth
+14.58% +3.46% -10.80% -4.54%
Gross Income
692.33M 969.60M 623.60M 396.01M
Gross Income Growth
+37.17% +40.05% -35.68% -36.50%
Gross Profit Margin
+32.92% +39.92% +32.39% +24.17%
2021 2022 2023 2024 5-year trend
SG&A Expense
452.91M 520.28M 451.07M 423.98M
Research & Development
56.05M 64.79M 70.51M 77.88M
Other SG&A
396.86M 455.48M 380.56M 346.09M
SGA Growth
+9.59% +14.88% -13.30% -6.01%
Other Operating Expense
- - (7.69M) 12.58M
-
Unusual Expense
25.02M 48.74M 12.05M 1.89M
EBIT after Unusual Expense
222.10M 387.99M 160.48M (29.85M)
Non Operating Income/Expense
(22.84M) (16.74M) 11.28M (20.10M)
Non-Operating Interest Income
1.41M 400.45K 1.79M 3.14M
Equity in Earnings of Affiliates
(15.76M) (20.84M) (14.41M) (23.78M)
Interest Expense
2.91M 3.52M 2.72M 2.76M
Interest Expense Growth
+37.73% +20.65% -22.54% +1.34%
Gross Interest Expense
2.91M 3.52M 2.72M 2.76M
Interest Capitalized
- - - -
-
Pretax Income
196.34M 367.73M 169.03M (52.69M)
Pretax Income Growth
+249.20% +87.30% -54.03% -131.17%
Pretax Margin
+9.34% +15.14% +8.78% -3.22%
Income Tax
32.04M 104.21M 53.35M (456.42K)
Income Tax - Current - Domestic
41.63M 88.14M 43.31M 26.44M
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
(9.58M) 16.07M 10.04M (26.90M)
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
(15.76M) (20.84M) (14.41M) (23.78M)
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
164.30M 263.52M 115.68M (52.23M)
Minority Interest Expense
- - (396.01K) 115.69K
-
Net Income
164.69M 263.40M 115.68M (52.23M)
Net Income Growth
+3,570.24% +59.93% -56.08% -145.15%
Net Margin Growth
+7.83% +10.84% +6.01% -3.19%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
164.69M 263.40M 115.68M (52.23M)
Preferred Dividends
- - - -
-
Net Income Available to Common
164.70M 263.40M 115.68M (52.23M)
EPS (Basic)
2.8888 4.6234 2.033 -0.9182
EPS (Basic) Growth
+3,567.95% +60.05% -56.03% -145.16%
Basic Shares Outstanding
57.01M 56.97M 56.90M 56.89M
EPS (Diluted)
2.8882 4.6223 2.0329 -0.9182
EPS (Diluted) Growth
+3,567.23% +60.04% -56.02% -145.17%
Diluted Shares Outstanding
57.03M 56.98M 56.90M 56.89M
EBITDA
364.92M 566.89M 317.86M 116.36M
EBITDA Growth
+86.54% +55.34% -43.93% -63.39%
EBITDA Margin
+17.35% +23.34% +16.51% +7.10%

Fujirebio in the News